stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Net income
Arcus Biosciences, Inc.'s net income for fiscal 2025 was −$353.0M, compared with −$283.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$453.0M. Over the past ten years it has ranged from −$353.0M (fiscal 2025) to $53.0M (fiscal 2021) — the current reading is the lowest in ten years. Arcus Biosciences, Inc. ranks 581st of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$353.0M | — |
| FY2024 | −$283.0M | — |
| FY2023 | −$307.0M | — |
| FY2022 | −$267.0M | — |
| FY2021 | $53.0M | — |
| FY2020 | −$123.0M | — |
| FY2019 | −$84.7M | — |
| FY2018 | −$49.6M | — |
| FY2017 | −$53.1M | — |
| FY2016 | −$18.0M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$128.0M | — |
| Jun 2026 | −$91.0M | — |
| Mar 2026 | −$128.0M | — |
| Dec 2025 | −$106.0M | — |
| 36 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| MBX MBX Biosciences, Inc. compare | −$104.3M |
| BEAM Beam Therapeutics Inc. compare | −$108.4M |
| XNCR Xencor, Inc. compare | −$163.3M |
| PHVS Pharvaris N.V. compare | −$193.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$198.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$204.9M |
| IDYA IDEAYA Biosciences, Inc. compare | −$420.0M |
| RCUS Arcus Biosciences, Inc. | −$453.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$475.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on RCUS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement